BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

The goal of this clinical trial is to learn the efficaty and safety of BC001 in combination with Sintilimab and XELOX in treating patients with advanced or metastatic GC/GEJ. Participants will: Be administered with BC001, Sintilimab and Oxaliplatin once every three weeks for up to 24 months or until disease progression as per RECIST 1.1 or withdrawal from this study. Take Capecitabine once daily in the first two weeks of each three-week treatment cycle for up to 24 months or until disease progression as per RECIST 1.1 or withdrawal from this study.

Trial Details

NCT ID
NCT06773312
Phase
PHASE1
Sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • BC001+Sintilimab+XELOX
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects must be able to understand and voluntarily sign the written informed consent.
  • Subjects must be willing and able to complete the study procedures and follow-up examinations.
  • Male or female subjects aged between 18 and 75 years old (including 18 and 75 years old).
  • HER-2 negative patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) (according to the 8th editi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →